“Major Breakthrough”: UK Trial Dexamethasone Drug Shows 1 to 3 Serious Kovid Cases

The results have been described as “major success”. (Representative)


Delivering low doses of the generic steroid drug dexamethasone to hospitalized patients with COVID-19 has reduced mortality around one-third of the most severe cases of infection, trial data showed on Tuesday.

Researchers said the drug, described as a “major breakthrough” by scientists known as RECOVERY in a UK-led clinical trial, should immediately become standard care in hospital-treated patients with pandemic disease, Researchers said.

“This is a result that shows that if COVID-19 and dexamethasone are given to patients if they are on ventilator or on oxygen, it will save lives, and it will do so at a lower cost,” said Martin Landre, Oxford University professor who is co-leading the test.

His co-chief investigator, Peter Horby, said that dexamethasone – a common steroid widely used in other diseases to reduce inflammation – is “the only drug shown to reduce mortality so far” Is – and it significantly reduces it. “

“It’s a huge success,” he said.

There are currently no approved treatments or vaccines for COVID-19, a disease caused by the new coronavirus that has killed more than 431,000 people globally.

(Except for the headline, this story has not been edited by NDTV staff and published from a syndicated feed.)

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *